Page last updated: 2024-10-24

candesartan and ADPKD

candesartan has been researched along with ADPKD in 1 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Research Excerpts

ExcerptRelevanceReference
"The renoprotective effect of candesartan is considered more favorable than amlodipine in the treatment of ADPKD."5.11Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. ( Higaki, Y; Higashihara, E; Horie, S; Hosoya, T; Kamura, K; Mochizuki, T; Nakayama, T; Nutahara, K; Shimizu, T; Tsuchiya, K; Yamamoto, N, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nutahara, K1
Higashihara, E1
Horie, S1
Kamura, K1
Tsuchiya, K1
Mochizuki, T1
Hosoya, T1
Nakayama, T1
Yamamoto, N1
Higaki, Y1
Shimizu, T1

Trials

1 trial available for candesartan and ADPKD

ArticleYear
Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nephron. Clinical practice, 2005, Volume: 99, Issue:1

    Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe

2005